Cancer

Worldwide Cancer Vaccines Industry to 2025 - Analysis of Promising Vaccines

Friday, September 18, 2020 - 8:00pm

This report provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market.

Key Points: 
  • This report provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market.
  • The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the global cancer vaccines market.
  • The report presents a clear perception of current and future developments of the global cancer vaccines market.
  • The report explores detailed insights into the introduction to cancer vaccines and the mechanism of cancer vaccines.

Japan Cancer Oncology Drug Therapeutics Market Sales Size Offers US$ 15 Billion Opportunity With 1600 Drug In Clinical Trials

Friday, September 18, 2020 - 3:57pm

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:
    Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
    Insight on Cancer Drugs In Clinical Trials: 360 Drugs
    Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
    Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
    Cancer Clinical Pipeline By Company, Indication & Phase
    Japan in the past few years have been observing influx in the record of novel oncology drugs that have been approved and getting used to treat millions of patients that are suffering from any type of cancer.
  • As per the report findings for Japan Cancer Drug Market, spending of the revenue in Japan is mostly concentrated towards the cancer types that have been prevailing badly in the country.
  • All this is estimated to impact the cancer drug market and the costs of the drug in Japan over the next decade.
  • Overall, the cancer drug market in Japan is estimated to reach numerous billion dollars in the coming years, leveraging the country to be the most dominant cancer drug market in Asia.

Japan Cancer Oncology Drug Therapeutics Market Sales Size Offers US$ 15 Billion Opportunity With 1600 Drug In Clinical Trials

Friday, September 18, 2020 - 3:59pm

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:
    Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
    Insight on Cancer Drugs In Clinical Trials: 360 Drugs
    Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
    Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
    Cancer Clinical Pipeline By Company, Indication & Phase
    Japan in the past few years have been observing influx in the record of novel oncology drugs that have been approved and getting used to treat millions of patients that are suffering from any type of cancer.
  • As per the report findings for Japan Cancer Drug Market, spending of the revenue in Japan is mostly concentrated towards the cancer types that have been prevailing badly in the country.
  • All this is estimated to impact the cancer drug market and the costs of the drug in Japan over the next decade.
  • Overall, the cancer drug market in Japan is estimated to reach numerous billion dollars in the coming years, leveraging the country to be the most dominant cancer drug market in Asia.

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

Friday, September 18, 2020 - 3:00pm

The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.

Key Points: 
  • The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.
  • The assembly of survival associations of individual markers from ONCOLNC.org into sets that will help identify novel targets in PDA.
  • Information about gene and protein function in human PDA patients and human PDA cancer cell lines to help prioritize individual diagnostic markers.
  • AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.

Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting

Friday, September 18, 2020 - 2:03pm

Natera will present four abstracts one oral and three poster presentations which highlight applications for detecting MRD levels and tracking tumor clonal evolution in CRC and in esophageal adenocarcinoma.

Key Points: 
  • Natera will present four abstracts one oral and three poster presentations which highlight applications for detecting MRD levels and tracking tumor clonal evolution in CRC and in esophageal adenocarcinoma.
  • "We're delighted to share new data at this year's ESMO meeting, which shows the broad potential of our tumor-informed approach to MRD assessment," said Alexey Aleshin, M.D., M.B.A., Senior Medical Director of Oncology at Natera.
  • "These studies demonstrate that Signatera provides clinically actionable information that can improve the management of patients with multiple different solid cancers."
  • Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.

Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer

Friday, September 18, 2020 - 1:30pm

Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.

Key Points: 
  • Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.
  • The initiation of the rolling BLA is an exciting step forward for Agenus as we are closer to making our therapies commercially available for patients with cervical cancer who have limited treatment options available, said Dr. Jennifer Buell, President and COO of Agenus.
  • A rolling submission allows Agenus to submit each section of the BLA as it is completed, which enables the FDA to review the submitted sections in parallel with Agenuss completion of the balance of the BLA application.
  • The American Cancer Society estimates around 14,000 new cases of invasive cervical cancer to be diagnosed this year and nearly 4,300 cervical cancer deaths.

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers

Friday, September 18, 2020 - 1:00pm

Brain metastasis is a significant concern in patients with TNBC, and we are very encouraged by these early-stage study results, stated Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics.

Key Points: 
  • Brain metastasis is a significant concern in patients with TNBC, and we are very encouraged by these early-stage study results, stated Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics.
  • European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
  • Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
  • Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer

Friday, September 18, 2020 - 12:30pm

The oral presentation is entitled Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent.

Key Points: 
  • The oral presentation is entitled Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent.
  • Based on these promising clinical data, VERU met with FDA on the Phase 3 clinical trial design in July 2020.
  • Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer.
  • VERU-111 is being evaluated in an open label Phase 1b/2 clinical study in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer.

LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo

Friday, September 18, 2020 - 12:00pm

Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in

Key Points: 
  • Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in
  • Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1).
  • Embryo-Fetal Toxicity: Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm.
  • Patients were randomized (2:1) to receive LYNPARZA or placebo for up to two years or until disease progression.

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Non-small Cell Lung Cancer With an Estimated 50% of Patients Surviving Four Years

Friday, September 18, 2020 - 12:00pm

With data also at ESMO for CASPIAN in small cell lung cancer patients, IMFINZI continues to deliver impressive long-term benefits across different types of lung cancer.

Key Points: 
  • With data also at ESMO for CASPIAN in small cell lung cancer patients, IMFINZI continues to deliver impressive long-term benefits across different types of lung cancer.
  • New exploratory subgroup analyses from the CASPIAN Phase III trial of IMFINZI were conducted to characterize patients deriving long-term benefit.
  • IMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
  • Sequential vs Concurrent Chemoradiation for Stage III NonSmall Cell Lung Cancer: Randomized Phase III Trial RTOG 9410.